Last reviewed · How we verify

Benadryl — Competitive Intelligence Brief

Benadryl (diphenhydramine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: First-generation antihistamine, Sedative. Area: Neuroscience.

marketed First-generation antihistamine, Sedative Histamine H4 receptor, Solute carrier family 22 member 2, 5-hydroxytryptamine receptor 2A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Benadryl (diphenhydramine) — Johnson & Johnson (McNeil Consumer Healthcare).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Benadryl TARGET diphenhydramine Johnson & Johnson (McNeil Consumer Healthcare) marketed First-generation antihistamine, Sedative Histamine H4 receptor, Solute carrier family 22 member 2, 5-hydroxytryptamine receptor 2A 1946-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (First-generation antihistamine, Sedative class)

  1. Johnson & Johnson (McNeil Consumer Healthcare) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Benadryl — Competitive Intelligence Brief. https://druglandscape.com/ci/diphenhydramine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: